For the FWIW column | OMER Message Board Posts

Omeros Corporation

  OMER website

OMER   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  2806 of 3368  at  2/6/2020 10:32:21 AM  by

Biotech_Jim


 In response to msg 2805 by  agrossfarm
view thread

Re: For the FWIW column

 Alan, you ask a very impt question that I have been pondering for quite some time.  
 
 One answer is that it is a test as to how any candidate compares to Soliris, in its prime indication, but that is obvious.  If it does not compare or is about equal, end of game for this candidate. 
 
 I may be overthinking this, but there are a lot of inflammatory kidney pathologies that could be launching points.  Lupus, several other nephridites.  I would venture to say most preclinical complement publications are related to kidney, but as I have delved into kidney diseases over time, this is complicated also.  
 
 Sorry that I cannot be of more help. But I was really struck by what George said in the CC.  And wondering about the RNAi target.


     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 2     Views: 256
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board

Replies
Msg # Subject Author Recs Date Posted
2807 Re: For the FWIW column agrossfarm 1 2/6/2020 10:55:00 AM






Financial Market Data provided by
.
Loading...